ArticleFrontiers in oncology2022

A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm.

Yijun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.